Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec 7;16(1):176.
doi: 10.1186/s12890-016-0333-y.

Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time

Mathew R Crull  1   2 , Kathleen J Ramos  3 , Ellen Caldwell  3 , Nicole Mayer-Hamblett  4   5 , Moira L Aitken  3 , Christopher H Goss  3   4
Affiliations

Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time

Mathew R Crull et al. BMC Pulm Med. .

Abstract

Background: Little is known about risk factors for chronic and mucoid Pseudomonas aeruginosa (Pa) infection in cystic fibrosis (CF) adults, and whether the prevalence is changing.

Methods: We employed a retrospective cohort to analyze data from a single adult CF center (2002 to 2012). Regression models were used to assess independent predictors and change in prevalence of chronic and mucoid Pa infection over time.

Results: The odds ratio of mucoid Pa infection was significantly less in individuals with better baseline lung function (OR 0.84,95%CI:0.77-0.92) and those diagnosed after the age of 25 (OR 0.21, 95%CI:0.05-0.95). The prevalence of chronic Pa and mucoid Pa decreased during the time interval. After adjusting for confounders, the observed decrease in chronic and mucoid Pa between 2002 and 2012 was no longer significant.

Conclusions: The prevalence of chronic and mucoid Pa is decreasing. Larger studies are needed to confirm these regional trends and their significance.

Keywords: Chronic infection; Cystic fibrosis; Epidemiology; Pseudomonas aeruginosa; Temporal trends.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
By time period, prevalence of chronic Pa by modified Leeds Criteria and mucoid Pa
See this image and copyright information in PMC

References

    1. Rogers GB, Hart CA, Mason JR, Hughes M, Walshaw MJ, Bruce KD. Bacterial Diversity in Cases of Lung Infection in Cystic Fibrosis Patients: 16S Ribosomal DNA (rDNA) Length Heterogeneity PCR and 16S rDNA Terminal Restriction Fragment Length Polymorphism Profiling. J Clin Microbiol. 2003;41(8):3548–3558. doi: 10.1128/JCM.41.8.3548-3558.2003. - DOI - PMC - PubMed
    1. MacKenzie T, Gifford AH, Sabadosa KA, Quinton HB, Knapp EA, Goss CH, et al. Longevity of Patients With Cystic Fibrosis in 2000 to 2010 and Beyond: Survival Analysis of the Cystic Fibrosis Foundation Patient Registry. Ann Intern Med. 2014;161(4):233–241. doi: 10.7326/M13-0636. - DOI - PMC - PubMed
    1. Cystic Fibrosis Foundation Patient Registry: 2013 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; 2014.
    1. Ratjen F, Döring G. Cystic fibrosis. Lancet. 2003;361(9358):681–689. doi: 10.1016/S0140-6736(03)12567-6. - DOI - PubMed
    1. Treggiari MM, Rosenfeld M, Retsch-Bogart G, Gibson R, Ramsey B. Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatr Pulmonol. 2007;42(9):751–756. doi: 10.1002/ppul.20665. - DOI - PubMed

Substances